Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun 5:6:277.
doi: 10.3389/fimmu.2015.00277. eCollection 2015.

Maraviroc - A CCR5 Antagonist for the Treatment of HIV-1 Infection

Elna Van Der Ryst  1
Affiliations
Review

Maraviroc - A CCR5 Antagonist for the Treatment of HIV-1 Infection

Elna Van Der Ryst. Front Immunol. .
No abstract available

Keywords: CCR5 antagonist; HIV; HIV-1 RNA; antiretroviral drug; tropism.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Maraviroc proof of concept and phase 3 efficacy results. (A) Mean maximum change from baseline in HIV-1 RNA in patients receiving MVC monotherapy. Based on phase 1 data and modeling and simulation, doses ranging from 25 mg QD to 300 mg BID (including 150 mg BID fed and fasted) were selected. HIV-1 RNA, safety, and MVC pharmacokinetics were evaluated (12). (B) MOTIVATE 1 and 2 – proportion of patients achieving HIV-1 RNA <50 copies/mL at week 48. HIV-1 infected patients with R5 HIV-1 and triple class experience and/or resistance were randomized to receive MVC QD or BID, or placebo, in combination with an optimized background antiretroviral regimen (OBT). P < 0.001 (13, 14).
See this image and copyright information in PMC

References

    1. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Schapiro MF, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS (2004) 18:1393–401.10.1097/01.aids.0000131310.52526.c7 - DOI - PubMed
    1. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 381:667–73.10.1038/381667a0 - DOI - PubMed
    1. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 272:872–7.10.1126/science.272.5263.872 - DOI - PubMed
    1. Berger EA, Doms RW, Fenyö EM, Korber BT, Littman DR, Moore JP, et al. A new classification for HIV-1. Nature (1998) 391:240.10.1038/34571 - DOI - PubMed
    1. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber C, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene. Nature (1996) 382:722–5.10.1038/382722a0 - DOI - PubMed